Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Bipolar Disorder | 232 | 2024 | 5027 | 18.670 |
Why?
|
Antipsychotic Agents | 134 | 2024 | 3057 | 9.990 |
Why?
|
Depressive Disorder, Major | 81 | 2023 | 4644 | 9.460 |
Why?
|
Antidepressive Agents | 73 | 2024 | 2838 | 7.300 |
Why?
|
Lithium | 50 | 2024 | 601 | 7.270 |
Why?
|
Antimanic Agents | 46 | 2024 | 522 | 7.260 |
Why?
|
Suicide, Attempted | 50 | 2023 | 1221 | 6.640 |
Why?
|
Suicide | 45 | 2023 | 1477 | 6.170 |
Why?
|
Mood Disorders | 24 | 2022 | 1106 | 4.310 |
Why?
|
Psychotic Disorders | 66 | 2023 | 3046 | 4.300 |
Why?
|
Suicidal Ideation | 26 | 2023 | 1248 | 4.100 |
Why?
|
Lithium Compounds | 21 | 2024 | 225 | 3.990 |
Why?
|
Psychotropic Drugs | 32 | 2023 | 894 | 3.390 |
Why?
|
Clozapine | 30 | 2023 | 498 | 3.350 |
Why?
|
Schizophrenia | 75 | 2023 | 6882 | 3.320 |
Why?
|
Temperament | 10 | 2023 | 283 | 3.200 |
Why?
|
Anticonvulsants | 37 | 2024 | 1916 | 3.150 |
Why?
|
Depressive Disorder | 59 | 2021 | 3748 | 3.050 |
Why?
|
Receptors, Dopamine D2 | 40 | 2008 | 475 | 2.990 |
Why?
|
Receptors, Dopamine | 62 | 2013 | 295 | 2.980 |
Why?
|
Antidepressive Agents, Tricyclic | 21 | 2020 | 434 | 2.830 |
Why?
|
Diagnostic and Statistical Manual of Mental Disorders | 36 | 2023 | 1953 | 2.120 |
Why?
|
Mental Disorders | 49 | 2022 | 6600 | 2.080 |
Why?
|
Serotonin | 40 | 2017 | 1017 | 2.050 |
Why?
|
Lithium Carbonate | 15 | 2010 | 184 | 2.030 |
Why?
|
Benzodiazepines | 20 | 2021 | 1101 | 1.940 |
Why?
|
Psychopharmacology | 4 | 2022 | 143 | 1.810 |
Why?
|
Valproic Acid | 13 | 2021 | 445 | 1.770 |
Why?
|
Pirenzepine | 9 | 2003 | 115 | 1.710 |
Why?
|
Depression | 24 | 2023 | 7766 | 1.710 |
Why?
|
Corpus Striatum | 54 | 2008 | 1221 | 1.630 |
Why?
|
Apomorphine | 56 | 2007 | 150 | 1.620 |
Why?
|
Dopamine | 70 | 2003 | 1591 | 1.600 |
Why?
|
Italy | 23 | 2021 | 832 | 1.570 |
Why?
|
Controlled Clinical Trials as Topic | 5 | 2015 | 187 | 1.520 |
Why?
|
Finasteride | 2 | 2021 | 90 | 1.490 |
Why?
|
Prosencephalon | 18 | 2008 | 303 | 1.490 |
Why?
|
Humans | 537 | 2024 | 744343 | 1.490 |
Why?
|
Risperidone | 13 | 2022 | 383 | 1.450 |
Why?
|
5-alpha Reductase Inhibitors | 2 | 2021 | 107 | 1.440 |
Why?
|
Hospitals, Psychiatric | 14 | 2019 | 332 | 1.430 |
Why?
|
Receptors, Dopamine D1 | 27 | 2008 | 291 | 1.380 |
Why?
|
Randomized Controlled Trials as Topic | 33 | 2022 | 9959 | 1.370 |
Why?
|
Psychiatric Status Rating Scales | 49 | 2017 | 6038 | 1.350 |
Why?
|
Anxiety Disorders | 17 | 2022 | 2690 | 1.350 |
Why?
|
Aporphines | 25 | 2008 | 32 | 1.330 |
Why?
|
Membrane Transport Proteins | 17 | 2005 | 1028 | 1.320 |
Why?
|
Dopamine Antagonists | 27 | 2007 | 296 | 1.310 |
Why?
|
Nucleus Accumbens | 22 | 2006 | 366 | 1.300 |
Why?
|
Psychiatry | 16 | 2014 | 1695 | 1.280 |
Why?
|
Drug Therapy, Combination | 46 | 2021 | 6489 | 1.270 |
Why?
|
Puerperal Disorders | 6 | 2023 | 275 | 1.220 |
Why?
|
Adult | 208 | 2024 | 214055 | 1.190 |
Why?
|
Fluoxetine | 12 | 2015 | 749 | 1.170 |
Why?
|
Male | 374 | 2024 | 350118 | 1.160 |
Why?
|
Cyclothymic Disorder | 4 | 2019 | 41 | 1.160 |
Why?
|
Rats | 211 | 2008 | 24260 | 1.120 |
Why?
|
Ketamine | 3 | 2023 | 500 | 1.100 |
Why?
|
Substance Withdrawal Syndrome | 20 | 2010 | 632 | 1.100 |
Why?
|
Oxidopamine | 14 | 2005 | 169 | 1.040 |
Why?
|
Hospitalization | 40 | 2023 | 10262 | 1.030 |
Why?
|
Recurrence | 43 | 2016 | 8340 | 1.010 |
Why?
|
Schizophrenic Psychology | 15 | 2017 | 1678 | 1.000 |
Why?
|
Female | 258 | 2024 | 380194 | 1.000 |
Why?
|
Caudate Nucleus | 19 | 2006 | 393 | 0.990 |
Why?
|
Risk Factors | 83 | 2023 | 72290 | 0.980 |
Why?
|
Imipramine | 8 | 2017 | 97 | 0.970 |
Why?
|
Haloperidol | 26 | 2023 | 397 | 0.950 |
Why?
|
Putamen | 11 | 2006 | 291 | 0.920 |
Why?
|
Age of Onset | 17 | 2022 | 3271 | 0.920 |
Why?
|
Hyperkinesis | 7 | 2005 | 89 | 0.910 |
Why?
|
Limbic System | 14 | 1999 | 426 | 0.890 |
Why?
|
Membrane Glycoproteins | 17 | 2005 | 3768 | 0.890 |
Why?
|
Xanthurenates | 2 | 2019 | 6 | 0.860 |
Why?
|
Affective Disorders, Psychotic | 7 | 2008 | 191 | 0.860 |
Why?
|
Lithium Chloride | 2 | 2014 | 87 | 0.840 |
Why?
|
Patient Dropouts | 3 | 2014 | 421 | 0.820 |
Why?
|
Carbamazepine | 7 | 2018 | 229 | 0.820 |
Why?
|
Rats, Sprague-Dawley | 54 | 2006 | 8301 | 0.810 |
Why?
|
Placebo Effect | 4 | 2014 | 502 | 0.800 |
Why?
|
Kynurenine | 2 | 2019 | 139 | 0.800 |
Why?
|
Dyskinesia, Drug-Induced | 14 | 2005 | 163 | 0.780 |
Why?
|
Triazines | 4 | 2018 | 315 | 0.780 |
Why?
|
Treatment Outcome | 80 | 2019 | 63114 | 0.780 |
Why?
|
Substance-Related Disorders | 14 | 2023 | 4258 | 0.770 |
Why?
|
Nerve Tissue Proteins | 19 | 2005 | 4462 | 0.770 |
Why?
|
Drug Utilization | 6 | 2010 | 1183 | 0.760 |
Why?
|
Alopecia | 2 | 2021 | 382 | 0.760 |
Why?
|
Dopamine Agents | 16 | 2013 | 189 | 0.750 |
Why?
|
Tryptophan | 7 | 2019 | 478 | 0.740 |
Why?
|
Motor Activity | 37 | 2012 | 2714 | 0.740 |
Why?
|
Drug Administration Schedule | 32 | 2015 | 4933 | 0.740 |
Why?
|
Drug Therapy | 5 | 2016 | 497 | 0.710 |
Why?
|
Secondary Prevention | 12 | 2015 | 1530 | 0.710 |
Why?
|
Appetite | 1 | 2022 | 243 | 0.710 |
Why?
|
Middle Aged | 129 | 2020 | 213383 | 0.680 |
Why?
|
Movement Disorders | 8 | 2011 | 445 | 0.680 |
Why?
|
Brain Chemistry | 24 | 2006 | 981 | 0.660 |
Why?
|
Dose-Response Relationship, Drug | 63 | 2021 | 10943 | 0.660 |
Why?
|
Chlorpromazine | 11 | 2017 | 111 | 0.660 |
Why?
|
Dibenzothiazepines | 6 | 2003 | 103 | 0.650 |
Why?
|
Receptors, Dopamine D4 | 18 | 2004 | 171 | 0.650 |
Why?
|
Carrier Proteins | 16 | 2004 | 5021 | 0.640 |
Why?
|
Community Mental Health Centers | 1 | 2018 | 102 | 0.630 |
Why?
|
Autoradiography | 20 | 2006 | 745 | 0.620 |
Why?
|
Neostriatum | 8 | 2004 | 250 | 0.620 |
Why?
|
Antidepressive Agents, Second-Generation | 4 | 2014 | 503 | 0.610 |
Why?
|
Pregnancy Complications | 9 | 2018 | 2861 | 0.610 |
Why?
|
Brain | 105 | 2018 | 26385 | 0.590 |
Why?
|
Cocaine | 19 | 2008 | 1007 | 0.580 |
Why?
|
Quinolones | 3 | 2005 | 367 | 0.580 |
Why?
|
Crisis Intervention | 1 | 2017 | 105 | 0.580 |
Why?
|
Risk | 20 | 2021 | 9687 | 0.570 |
Why?
|
Goals | 1 | 2022 | 706 | 0.570 |
Why?
|
Meta-Analysis as Topic | 6 | 2023 | 1344 | 0.570 |
Why?
|
Patient Compliance | 5 | 2008 | 2684 | 0.560 |
Why?
|
Attention Deficit Disorder with Hyperactivity | 15 | 2018 | 3658 | 0.560 |
Why?
|
Law Enforcement | 1 | 2017 | 109 | 0.560 |
Why?
|
Spinal Dysraphism | 1 | 2018 | 161 | 0.550 |
Why?
|
Schizophrenia, Paranoid | 2 | 2016 | 104 | 0.540 |
Why?
|
Attention Deficit and Disruptive Behavior Disorders | 1 | 2018 | 304 | 0.540 |
Why?
|
Affective Symptoms | 5 | 2016 | 407 | 0.540 |
Why?
|
Comorbidity | 20 | 2019 | 10388 | 0.540 |
Why?
|
Police | 1 | 2017 | 149 | 0.540 |
Why?
|
Multivariate Analysis | 13 | 2016 | 12245 | 0.540 |
Why?
|
Violence | 3 | 2017 | 909 | 0.530 |
Why?
|
Neural Tube Defects | 1 | 2018 | 256 | 0.530 |
Why?
|
Morbidity | 7 | 2021 | 1769 | 0.530 |
Why?
|
Tetrahydronaphthalenes | 14 | 1998 | 89 | 0.530 |
Why?
|
Periodicity | 4 | 2008 | 363 | 0.530 |
Why?
|
Prevalence | 24 | 2023 | 15226 | 0.520 |
Why?
|
Weight Gain | 2 | 2022 | 2292 | 0.520 |
Why?
|
Alkylating Agents | 5 | 2000 | 139 | 0.520 |
Why?
|
Receptors, Glutamate | 4 | 2003 | 232 | 0.520 |
Why?
|
Time Factors | 65 | 2019 | 40075 | 0.520 |
Why?
|
Delayed-Action Preparations | 7 | 2023 | 968 | 0.510 |
Why?
|
Anxiety | 7 | 2023 | 4297 | 0.500 |
Why?
|
Norepinephrine | 37 | 2002 | 909 | 0.500 |
Why?
|
Radioligand Assay | 25 | 2008 | 374 | 0.500 |
Why?
|
Amphetamine | 12 | 2000 | 225 | 0.500 |
Why?
|
Animals, Newborn | 12 | 2005 | 2726 | 0.500 |
Why?
|
Epilepsy | 6 | 2014 | 3310 | 0.490 |
Why?
|
Longitudinal Studies | 16 | 2022 | 13989 | 0.490 |
Why?
|
Piperazines | 7 | 2005 | 2488 | 0.490 |
Why?
|
Capgras Syndrome | 1 | 2014 | 9 | 0.490 |
Why?
|
Animals | 252 | 2021 | 168757 | 0.490 |
Why?
|
Monoamine Oxidase Inhibitors | 13 | 2012 | 158 | 0.490 |
Why?
|
Age Factors | 32 | 2018 | 18370 | 0.490 |
Why?
|
Adrenergic Uptake Inhibitors | 5 | 2008 | 189 | 0.480 |
Why?
|
Menarche | 1 | 2016 | 516 | 0.470 |
Why?
|
Rats, Inbred Strains | 46 | 1992 | 2186 | 0.470 |
Why?
|
Dermatitis, Atopic | 1 | 2020 | 654 | 0.470 |
Why?
|
Arsenic | 1 | 2017 | 328 | 0.470 |
Why?
|
Psychopathology | 4 | 2018 | 409 | 0.470 |
Why?
|
History, 19th Century | 11 | 2017 | 720 | 0.460 |
Why?
|
Basal Ganglia Diseases | 5 | 2011 | 149 | 0.460 |
Why?
|
Dopamine Agonists | 7 | 2012 | 355 | 0.460 |
Why?
|
Publishing | 3 | 2013 | 833 | 0.460 |
Why?
|
Severity of Illness Index | 25 | 2020 | 15540 | 0.450 |
Why?
|
Thiophenes | 2 | 2009 | 588 | 0.450 |
Why?
|
Probiotics | 1 | 2017 | 351 | 0.440 |
Why?
|
Self-Injurious Behavior | 2 | 2015 | 465 | 0.440 |
Why?
|
Drug Prescriptions | 7 | 2020 | 1637 | 0.430 |
Why?
|
Psoriasis | 1 | 2020 | 898 | 0.430 |
Why?
|
Hydroxyindoleacetic Acid | 11 | 2019 | 90 | 0.430 |
Why?
|
Recovery of Function | 5 | 2010 | 2925 | 0.420 |
Why?
|
Serotonin Plasma Membrane Transport Proteins | 13 | 2008 | 322 | 0.420 |
Why?
|
Stereotyped Behavior | 24 | 2001 | 136 | 0.420 |
Why?
|
Desipramine | 20 | 2005 | 184 | 0.410 |
Why?
|
Stereoisomerism | 30 | 2008 | 624 | 0.410 |
Why?
|
Clinical Trials as Topic | 17 | 2019 | 7913 | 0.410 |
Why?
|
Dopamine Plasma Membrane Transport Proteins | 17 | 2006 | 422 | 0.400 |
Why?
|
Young Adult | 30 | 2022 | 56430 | 0.400 |
Why?
|
Follow-Up Studies | 35 | 2018 | 39050 | 0.400 |
Why?
|
Adolescent | 57 | 2022 | 85781 | 0.400 |
Why?
|
Folic Acid | 2 | 2018 | 1300 | 0.390 |
Why?
|
Reproductive Behavior | 1 | 2011 | 29 | 0.390 |
Why?
|
Sex Factors | 23 | 2020 | 10397 | 0.380 |
Why?
|
Benzothiazoles | 1 | 2011 | 248 | 0.380 |
Why?
|
Anti-Inflammatory Agents | 2 | 2019 | 1790 | 0.380 |
Why?
|
Cause of Death | 5 | 2017 | 3584 | 0.380 |
Why?
|
Survival Analysis | 19 | 2022 | 10252 | 0.370 |
Why?
|
Tropanes | 8 | 2006 | 51 | 0.370 |
Why?
|
Somatoform Disorders | 1 | 2013 | 423 | 0.370 |
Why?
|
Tritium | 35 | 2002 | 745 | 0.370 |
Why?
|
Biological Clocks | 1 | 2012 | 321 | 0.370 |
Why?
|
Behavior, Animal | 24 | 1994 | 1881 | 0.370 |
Why?
|
Withholding Treatment | 1 | 2014 | 599 | 0.370 |
Why?
|
Receptors, Serotonin | 7 | 2002 | 201 | 0.360 |
Why?
|
Structure-Activity Relationship | 34 | 2008 | 3129 | 0.360 |
Why?
|
Neuropsychological Tests | 6 | 2018 | 6993 | 0.360 |
Why?
|
Phenothiazines | 4 | 2008 | 63 | 0.360 |
Why?
|
Polypharmacy | 3 | 2010 | 294 | 0.350 |
Why?
|
Benzazepines | 7 | 2003 | 326 | 0.350 |
Why?
|
Research Report | 1 | 2013 | 355 | 0.350 |
Why?
|
Psychometrics | 3 | 2018 | 3002 | 0.350 |
Why?
|
Birth Rate | 1 | 2011 | 170 | 0.350 |
Why?
|
Sympatholytics | 6 | 2001 | 83 | 0.350 |
Why?
|
Thinking | 2 | 2017 | 319 | 0.350 |
Why?
|
Consensus Development Conferences as Topic | 1 | 2010 | 170 | 0.340 |
Why?
|
Cognition Disorders | 6 | 2010 | 4043 | 0.340 |
Why?
|
Asia | 6 | 2020 | 610 | 0.340 |
Why?
|
Circadian Rhythm | 11 | 2012 | 2624 | 0.340 |
Why?
|
Siblings | 1 | 2013 | 854 | 0.340 |
Why?
|
Cross-Cultural Comparison | 2 | 2010 | 651 | 0.340 |
Why?
|
Panic Disorder | 3 | 2014 | 616 | 0.330 |
Why?
|
Excitatory Amino Acid Antagonists | 3 | 2015 | 449 | 0.330 |
Why?
|
Fatty Acids | 1 | 2017 | 1809 | 0.330 |
Why?
|
Synaptosomes | 22 | 2000 | 115 | 0.330 |
Why?
|
Argentina | 4 | 2015 | 232 | 0.330 |
Why?
|
Selection, Genetic | 1 | 2013 | 914 | 0.320 |
Why?
|
Personality Inventory | 5 | 2021 | 1030 | 0.320 |
Why?
|
Bupropion | 2 | 2003 | 303 | 0.320 |
Why?
|
Substantia Nigra | 5 | 2001 | 353 | 0.320 |
Why?
|
Patient Discharge | 4 | 2019 | 3313 | 0.320 |
Why?
|
Bayes Theorem | 6 | 2016 | 2309 | 0.320 |
Why?
|
Risk Assessment | 21 | 2019 | 23338 | 0.320 |
Why?
|
International Cooperation | 3 | 2010 | 1420 | 0.320 |
Why?
|
Length of Stay | 9 | 2016 | 6309 | 0.310 |
Why?
|
Neurosyphilis | 1 | 2008 | 22 | 0.310 |
Why?
|
Child | 39 | 2022 | 77709 | 0.310 |
Why?
|
Perinatal Care | 1 | 2010 | 227 | 0.310 |
Why?
|
Convalescence | 1 | 2008 | 105 | 0.310 |
Why?
|
Epidemiologic Research Design | 1 | 2011 | 367 | 0.300 |
Why?
|
Double-Blind Method | 17 | 2017 | 12026 | 0.300 |
Why?
|
History, 20th Century | 11 | 2017 | 2740 | 0.300 |
Why?
|
Tyrosine 3-Monooxygenase | 12 | 2005 | 375 | 0.300 |
Why?
|
Attitude to Health | 3 | 2014 | 2052 | 0.300 |
Why?
|
Chronobiology Disorders | 1 | 2008 | 74 | 0.290 |
Why?
|
Mental Health | 2 | 2018 | 3019 | 0.290 |
Why?
|
Piracetam | 1 | 2007 | 87 | 0.290 |
Why?
|
2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine | 4 | 2003 | 54 | 0.290 |
Why?
|
Fluphenazine | 8 | 2006 | 36 | 0.290 |
Why?
|
Ecology | 1 | 2007 | 106 | 0.290 |
Why?
|
Placebos | 8 | 2013 | 1676 | 0.290 |
Why?
|
Akathisia, Drug-Induced | 2 | 2006 | 67 | 0.290 |
Why?
|
Abnormalities, Drug-Induced | 3 | 2007 | 317 | 0.290 |
Why?
|
Prospective Studies | 25 | 2023 | 53288 | 0.280 |
Why?
|
Malaria, Cerebral | 1 | 2008 | 135 | 0.280 |
Why?
|
Accidents | 1 | 2007 | 164 | 0.280 |
Why?
|
Dihydroxyphenylalanine | 15 | 1994 | 76 | 0.280 |
Why?
|
Nootropic Agents | 1 | 2007 | 160 | 0.280 |
Why?
|
Logistic Models | 9 | 2018 | 13408 | 0.280 |
Why?
|
Salts | 2 | 2024 | 65 | 0.280 |
Why?
|
Drug Labeling | 2 | 2009 | 233 | 0.270 |
Why?
|
Symporters | 5 | 2005 | 362 | 0.270 |
Why?
|
Antioxidants | 2 | 2011 | 1663 | 0.270 |
Why?
|
Demography | 5 | 2015 | 1656 | 0.270 |
Why?
|
Overweight | 3 | 2021 | 2371 | 0.270 |
Why?
|
Research Design | 8 | 2018 | 5987 | 0.270 |
Why?
|
Family Characteristics | 1 | 2011 | 1000 | 0.270 |
Why?
|
Psychological Theory | 3 | 2011 | 168 | 0.270 |
Why?
|
Irritable Mood | 4 | 2021 | 183 | 0.270 |
Why?
|
Drug Tolerance | 5 | 2019 | 376 | 0.260 |
Why?
|
Catecholamines | 16 | 1991 | 387 | 0.260 |
Why?
|
Receptors, Kainic Acid | 4 | 2004 | 88 | 0.260 |
Why?
|
Leukopenia | 5 | 2015 | 212 | 0.260 |
Why?
|
S-Adenosylmethionine | 11 | 1987 | 212 | 0.260 |
Why?
|
Sex Distribution | 6 | 2015 | 2297 | 0.250 |
Why?
|
Spiperone | 8 | 1999 | 31 | 0.250 |
Why?
|
Postpartum Period | 1 | 2011 | 1086 | 0.250 |
Why?
|
Coffee | 1 | 2009 | 578 | 0.250 |
Why?
|
Methionine | 16 | 1979 | 590 | 0.250 |
Why?
|
Denervation | 6 | 2001 | 278 | 0.250 |
Why?
|
Long-Term Care | 8 | 2008 | 607 | 0.250 |
Why?
|
GTP-Binding Proteins | 2 | 2000 | 970 | 0.250 |
Why?
|
Quinolines | 5 | 2000 | 732 | 0.250 |
Why?
|
Cross-Sectional Studies | 16 | 2024 | 25043 | 0.250 |
Why?
|
Retrospective Studies | 27 | 2023 | 77449 | 0.250 |
Why?
|
Obsessive-Compulsive Disorder | 4 | 2008 | 1444 | 0.240 |
Why?
|
Kainic Acid | 3 | 1999 | 199 | 0.240 |
Why?
|
Marijuana Abuse | 1 | 2008 | 403 | 0.240 |
Why?
|
Germany | 6 | 2016 | 862 | 0.240 |
Why?
|
Hyperthermia, Induced | 1 | 2008 | 403 | 0.240 |
Why?
|
Cardiomyopathies | 1 | 2016 | 1912 | 0.240 |
Why?
|
Neurology | 2 | 2010 | 763 | 0.240 |
Why?
|
Prognosis | 17 | 2018 | 29063 | 0.240 |
Why?
|
Naphthalenes | 5 | 1988 | 194 | 0.240 |
Why?
|
Philosophy | 1 | 2004 | 66 | 0.240 |
Why?
|
Extrapyramidal Tracts | 4 | 2002 | 18 | 0.240 |
Why?
|
Delusions | 6 | 2021 | 300 | 0.240 |
Why?
|
Receptors, N-Methyl-D-Aspartate | 4 | 2004 | 895 | 0.230 |
Why?
|
Piperidines | 8 | 2006 | 1602 | 0.230 |
Why?
|
Prolactin | 3 | 2011 | 669 | 0.230 |
Why?
|
Receptors, AMPA | 4 | 2004 | 331 | 0.230 |
Why?
|
Disability Evaluation | 2 | 2010 | 1827 | 0.230 |
Why?
|
Hippocampus | 9 | 2006 | 3675 | 0.230 |
Why?
|
Environmental Exposure | 1 | 2018 | 4234 | 0.220 |
Why?
|
Arousal | 8 | 2013 | 1165 | 0.220 |
Why?
|
Incidence | 11 | 2019 | 20947 | 0.220 |
Why?
|
Combined Modality Therapy | 7 | 2015 | 8642 | 0.220 |
Why?
|
Pregnancy | 15 | 2018 | 29144 | 0.220 |
Why?
|
Acute Disease | 13 | 2011 | 7149 | 0.220 |
Why?
|
Cognition | 3 | 2013 | 6770 | 0.220 |
Why?
|
Ventricular Function, Left | 1 | 2015 | 3670 | 0.220 |
Why?
|
Treatment Refusal | 3 | 2002 | 421 | 0.220 |
Why?
|
Adrenergic Agents | 4 | 2005 | 70 | 0.210 |
Why?
|
Sympathectomy, Chemical | 1 | 2001 | 22 | 0.210 |
Why?
|
Thyroid Hormones | 2 | 2012 | 390 | 0.210 |
Why?
|
Outpatients | 4 | 2014 | 1486 | 0.210 |
Why?
|
Death, Sudden, Cardiac | 2 | 2009 | 1541 | 0.210 |
Why?
|
Europe | 5 | 2013 | 3339 | 0.210 |
Why?
|
Psychotherapy | 5 | 2023 | 1643 | 0.210 |
Why?
|
Databases, Bibliographic | 2 | 2015 | 128 | 0.210 |
Why?
|
Electroconvulsive Therapy | 7 | 2012 | 477 | 0.210 |
Why?
|
5-Hydroxytryptophan | 9 | 1980 | 32 | 0.200 |
Why?
|
Parasympatholytics | 5 | 1992 | 91 | 0.200 |
Why?
|
Child Psychiatry | 1 | 2004 | 220 | 0.200 |
Why?
|
Biogenic Amines | 7 | 2004 | 50 | 0.200 |
Why?
|
Neurotoxins | 2 | 2003 | 237 | 0.200 |
Why?
|
Interview, Psychological | 3 | 2011 | 812 | 0.200 |
Why?
|
Sertraline | 3 | 1999 | 206 | 0.200 |
Why?
|
Aged | 46 | 2018 | 163280 | 0.200 |
Why?
|
Norepinephrine Plasma Membrane Transport Proteins | 7 | 2006 | 66 | 0.200 |
Why?
|
Striatonigral Degeneration | 1 | 2000 | 13 | 0.190 |
Why?
|
Central Nervous System Stimulants | 4 | 2004 | 1148 | 0.190 |
Why?
|
Prefrontal Cortex | 5 | 2000 | 2147 | 0.190 |
Why?
|
Inpatients | 5 | 2016 | 2518 | 0.190 |
Why?
|
Alcoholism | 2 | 2008 | 1906 | 0.190 |
Why?
|
Antimalarials | 1 | 2008 | 905 | 0.190 |
Why?
|
Binding, Competitive | 15 | 2008 | 1157 | 0.190 |
Why?
|
Spain | 5 | 2013 | 465 | 0.190 |
Why?
|
Biogenic Monoamines | 3 | 2004 | 50 | 0.190 |
Why?
|
Synaptic Transmission | 11 | 2004 | 1178 | 0.190 |
Why?
|
Drug Interactions | 14 | 2001 | 1460 | 0.180 |
Why?
|
Dexamethasone | 8 | 1988 | 1951 | 0.180 |
Why?
|
Visual Cortex | 2 | 1999 | 1149 | 0.180 |
Why?
|
Nervous System Diseases | 5 | 2018 | 1622 | 0.180 |
Why?
|
Presynaptic Terminals | 1 | 2002 | 302 | 0.180 |
Why?
|
Mental Health Services | 3 | 2017 | 1643 | 0.180 |
Why?
|
Hydrocortisone | 9 | 2015 | 1826 | 0.180 |
Why?
|
Long QT Syndrome | 1 | 2004 | 453 | 0.180 |
Why?
|
Biological Psychiatry | 1 | 1999 | 25 | 0.180 |
Why?
|
Receptors, Dopamine D3 | 7 | 2001 | 110 | 0.180 |
Why?
|
Thiazoles | 2 | 2004 | 1483 | 0.180 |
Why?
|
Receptors, GABA-B | 1 | 2000 | 68 | 0.180 |
Why?
|
Ergolines | 3 | 1994 | 61 | 0.180 |
Why?
|
Amphetamine-Related Disorders | 1 | 2000 | 67 | 0.180 |
Why?
|
Dihydroxytryptamines | 4 | 1980 | 6 | 0.180 |
Why?
|
Drugs, Investigational | 1 | 2002 | 214 | 0.170 |
Why?
|
Nitric Oxide Synthase | 1 | 2002 | 916 | 0.170 |
Why?
|
Catalepsy | 9 | 2001 | 34 | 0.170 |
Why?
|
Mass Screening | 2 | 2018 | 5255 | 0.170 |
Why?
|
Nerve Endings | 10 | 2002 | 109 | 0.170 |
Why?
|
Amines | 7 | 1988 | 276 | 0.170 |
Why?
|
Quinolinic Acid | 1 | 2019 | 67 | 0.170 |
Why?
|
Kynurenic Acid | 1 | 2019 | 46 | 0.170 |
Why?
|
Neurotransmitter Agents | 11 | 1983 | 647 | 0.170 |
Why?
|
Urban Population | 2 | 2021 | 2021 | 0.170 |
Why?
|
Hallucinations | 3 | 2014 | 360 | 0.170 |
Why?
|
Disease Progression | 7 | 2019 | 13284 | 0.170 |
Why?
|
Iodine Radioisotopes | 4 | 2008 | 1032 | 0.170 |
Why?
|
Polycystic Ovary Syndrome | 1 | 2003 | 370 | 0.170 |
Why?
|
History, 18th Century | 2 | 2017 | 214 | 0.170 |
Why?
|
Kinetics | 27 | 2008 | 6473 | 0.160 |
Why?
|
Outpatient Clinics, Hospital | 1 | 2001 | 392 | 0.160 |
Why?
|
Attitude of Health Personnel | 2 | 2010 | 3843 | 0.160 |
Why?
|
Pharmacoepidemiology | 5 | 2024 | 323 | 0.160 |
Why?
|
Cerebral Cortex | 19 | 2006 | 5708 | 0.160 |
Why?
|
Methylphenidate | 2 | 2001 | 473 | 0.160 |
Why?
|
Clorgyline | 1 | 1997 | 14 | 0.160 |
Why?
|
Hypothyroidism | 1 | 2023 | 658 | 0.160 |
Why?
|
Selegiline | 1 | 1997 | 31 | 0.160 |
Why?
|
Self Concept | 2 | 2016 | 1025 | 0.160 |
Why?
|
Gender Identity | 1 | 2023 | 688 | 0.160 |
Why?
|
Amides | 1 | 2001 | 459 | 0.160 |
Why?
|
Memory, Short-Term | 1 | 2004 | 975 | 0.160 |
Why?
|
National Institute of Mental Health (U.S.) | 1 | 1998 | 107 | 0.160 |
Why?
|
Analgesics | 3 | 2013 | 1040 | 0.150 |
Why?
|
Sexual Dysfunction, Physiological | 1 | 2021 | 360 | 0.150 |
Why?
|
Massachusetts | 6 | 2016 | 8663 | 0.150 |
Why?
|
Analysis of Variance | 9 | 2012 | 6365 | 0.150 |
Why?
|
Colorado | 1 | 2017 | 163 | 0.150 |
Why?
|
Nerve Degeneration | 3 | 1999 | 748 | 0.150 |
Why?
|
Molecular Structure | 10 | 2007 | 1899 | 0.150 |
Why?
|
Rorschach Test | 1 | 2017 | 26 | 0.150 |
Why?
|
Tryptamines | 6 | 1979 | 88 | 0.150 |
Why?
|
Research | 2 | 2005 | 1999 | 0.150 |
Why?
|
Entorhinal Cortex | 3 | 2006 | 272 | 0.150 |
Why?
|
Tissue Banks | 1 | 2018 | 184 | 0.150 |
Why?
|
5,7-Dihydroxytryptamine | 4 | 1980 | 13 | 0.150 |
Why?
|
Prostatic Hyperplasia | 1 | 2021 | 523 | 0.150 |
Why?
|
Diagnosis | 1 | 2018 | 154 | 0.140 |
Why?
|
Marital Status | 2 | 2017 | 437 | 0.140 |
Why?
|
Neuronal Plasticity | 2 | 2002 | 1422 | 0.140 |
Why?
|
ROC Curve | 2 | 2014 | 3527 | 0.140 |
Why?
|
Advisory Committees | 4 | 2019 | 775 | 0.140 |
Why?
|
Infertility, Female | 1 | 2002 | 787 | 0.140 |
Why?
|
Linear Models | 4 | 2015 | 5952 | 0.140 |
Why?
|
Cyclic AMP | 10 | 1990 | 1472 | 0.140 |
Why?
|
Registries | 2 | 2015 | 8089 | 0.140 |
Why?
|
Agranulocytosis | 2 | 2015 | 101 | 0.140 |
Why?
|
United States | 20 | 2011 | 69872 | 0.140 |
Why?
|
Episode of Care | 2 | 2013 | 126 | 0.140 |
Why?
|
Chi-Square Distribution | 3 | 2010 | 3508 | 0.140 |
Why?
|
International Classification of Diseases | 3 | 2013 | 867 | 0.130 |
Why?
|
Drug Combinations | 2 | 2015 | 1959 | 0.130 |
Why?
|
Tomography, Emission-Computed, Single-Photon | 4 | 2008 | 1107 | 0.130 |
Why?
|
Diagnostic Errors | 3 | 2013 | 1257 | 0.130 |
Why?
|
Methyltransferases | 8 | 1978 | 367 | 0.130 |
Why?
|
Evidence-Based Medicine | 3 | 2014 | 3610 | 0.130 |
Why?
|
Water Supply | 1 | 2017 | 214 | 0.130 |
Why?
|
Off-Label Use | 3 | 2014 | 169 | 0.130 |
Why?
|
Receptor, Serotonin, 5-HT2A | 4 | 2002 | 63 | 0.130 |
Why?
|
Patient Admission | 3 | 2005 | 1380 | 0.130 |
Why?
|
Dysthymic Disorder | 2 | 2010 | 74 | 0.130 |
Why?
|
Benzamides | 5 | 2003 | 1379 | 0.130 |
Why?
|
Benztropine | 3 | 1991 | 17 | 0.130 |
Why?
|
Stress, Psychological | 3 | 2015 | 4245 | 0.130 |
Why?
|
Receptors, sigma | 5 | 1995 | 28 | 0.130 |
Why?
|
Aging | 9 | 2003 | 8664 | 0.120 |
Why?
|
Socioeconomic Factors | 6 | 2013 | 7785 | 0.120 |
Why?
|
Weight Loss | 1 | 2006 | 2622 | 0.120 |
Why?
|
Affect | 3 | 2013 | 1476 | 0.120 |
Why?
|
Obesity | 3 | 2006 | 12745 | 0.120 |
Why?
|
Behavioral Symptoms | 1 | 2016 | 175 | 0.120 |
Why?
|
Radiopharmaceuticals | 4 | 2008 | 2645 | 0.120 |
Why?
|
Injections | 4 | 2020 | 840 | 0.120 |
Why?
|
Molecular Probes | 2 | 1996 | 316 | 0.120 |
Why?
|
Docosahexaenoic Acids | 1 | 2001 | 875 | 0.120 |
Why?
|
Memantine | 1 | 2015 | 100 | 0.120 |
Why?
|
Steroids | 1 | 2019 | 930 | 0.120 |
Why?
|
Physician-Patient Relations | 2 | 2022 | 3229 | 0.120 |
Why?
|
Myoclonus | 4 | 1979 | 104 | 0.120 |
Why?
|
Human Development | 1 | 2014 | 124 | 0.120 |
Why?
|
Family Health | 3 | 2015 | 1282 | 0.120 |
Why?
|
Sculpture | 1 | 2013 | 6 | 0.110 |
Why?
|
Ligands | 11 | 2007 | 3282 | 0.110 |
Why?
|
Child Behavior | 1 | 2019 | 839 | 0.110 |
Why?
|
Delirium | 4 | 2003 | 1609 | 0.110 |
Why?
|
Age Distribution | 3 | 2015 | 2902 | 0.110 |
Why?
|
Smoking Cessation | 1 | 2005 | 2071 | 0.110 |
Why?
|
Homicide | 1 | 2016 | 287 | 0.110 |
Why?
|
Research Support as Topic | 1 | 1998 | 705 | 0.110 |
Why?
|
gamma-Aminobutyric Acid | 4 | 1985 | 1121 | 0.110 |
Why?
|
Chronic Disease | 8 | 2010 | 9146 | 0.110 |
Why?
|
Databases, Factual | 4 | 2014 | 7729 | 0.110 |
Why?
|
Borderline Personality Disorder | 1 | 2020 | 736 | 0.110 |
Why?
|
Receptors, Muscarinic | 3 | 1988 | 156 | 0.110 |
Why?
|
Emotions | 2 | 2016 | 2661 | 0.110 |
Why?
|
Neuroprotective Agents | 1 | 1999 | 941 | 0.110 |
Why?
|
Alzheimer Disease | 3 | 2007 | 8037 | 0.110 |
Why?
|
Pyridines | 6 | 2004 | 2825 | 0.110 |
Why?
|
Adverse Drug Reaction Reporting Systems | 1 | 2016 | 469 | 0.110 |
Why?
|
Research Personnel | 1 | 1998 | 573 | 0.110 |
Why?
|
Receptors, Opioid | 2 | 1991 | 155 | 0.110 |
Why?
|
Pilot Projects | 4 | 2017 | 8324 | 0.110 |
Why?
|
Diagnosis, Differential | 13 | 2012 | 12959 | 0.110 |
Why?
|
Early Diagnosis | 1 | 2018 | 1184 | 0.110 |
Why?
|
Rhenium | 3 | 2002 | 13 | 0.110 |
Why?
|
Multicenter Studies as Topic | 2 | 2011 | 1677 | 0.110 |
Why?
|
3,4-Dihydroxyphenylacetic Acid | 6 | 1998 | 64 | 0.110 |
Why?
|
Risk Adjustment | 1 | 2016 | 594 | 0.110 |
Why?
|
Hospitals, University | 2 | 2016 | 571 | 0.110 |
Why?
|
Tranquilizing Agents | 5 | 1977 | 59 | 0.110 |
Why?
|
Smoking | 1 | 2009 | 8987 | 0.110 |
Why?
|
Receptors, Drug | 6 | 1979 | 160 | 0.110 |
Why?
|
Drug Synergism | 6 | 2011 | 1792 | 0.110 |
Why?
|
Thioridazine | 6 | 1995 | 33 | 0.110 |
Why?
|
Forecasting | 2 | 2014 | 2951 | 0.100 |
Why?
|
Behavior | 4 | 1977 | 561 | 0.100 |
Why?
|
Benzomorphans | 1 | 1991 | 5 | 0.100 |
Why?
|
Administration, Oral | 10 | 2010 | 3913 | 0.100 |
Why?
|
Acculturation | 1 | 2013 | 182 | 0.100 |
Why?
|
Esters | 5 | 2008 | 210 | 0.100 |
Why?
|
Disease Susceptibility | 1 | 1999 | 1782 | 0.100 |
Why?
|
Hepatic Encephalopathy | 5 | 1977 | 139 | 0.100 |
Why?
|
Homovanillic Acid | 4 | 1998 | 75 | 0.100 |
Why?
|
Nomifensine | 1 | 1991 | 15 | 0.100 |
Why?
|
Chromatography, High Pressure Liquid | 8 | 2008 | 1572 | 0.100 |
Why?
|
Triage | 1 | 2018 | 976 | 0.100 |
Why?
|
Hypothalamo-Hypophyseal System | 3 | 2015 | 703 | 0.100 |
Why?
|
Troponin I | 1 | 2015 | 619 | 0.100 |
Why?
|
Delphi Technique | 2 | 2013 | 778 | 0.100 |
Why?
|
Central Nervous System | 7 | 1978 | 1357 | 0.100 |
Why?
|
Amygdala | 2 | 1998 | 1315 | 0.100 |
Why?
|
Neurotensin | 1 | 1991 | 61 | 0.090 |
Why?
|
Guilt | 1 | 2011 | 95 | 0.090 |
Why?
|
Employment | 1 | 2017 | 1132 | 0.090 |
Why?
|
Receptor, Serotonin, 5-HT1A | 2 | 2008 | 53 | 0.090 |
Why?
|
Adolescent Behavior | 1 | 2019 | 1151 | 0.090 |
Why?
|
Predictive Value of Tests | 6 | 2015 | 15076 | 0.090 |
Why?
|
8-Hydroxy-2-(di-n-propylamino)tetralin | 2 | 1988 | 32 | 0.090 |
Why?
|
Pharmacy Service, Hospital | 2 | 2005 | 133 | 0.090 |
Why?
|
Association | 1 | 2010 | 53 | 0.090 |
Why?
|
Perception | 1 | 2017 | 1198 | 0.090 |
Why?
|
Phenethylamines | 6 | 1981 | 96 | 0.090 |
Why?
|
Publication Bias | 1 | 2011 | 162 | 0.090 |
Why?
|
Causality | 1 | 2016 | 1275 | 0.090 |
Why?
|
Drug Monitoring | 1 | 2016 | 956 | 0.090 |
Why?
|
Thyroid Gland | 1 | 1997 | 1173 | 0.090 |
Why?
|
Stimulation, Chemical | 7 | 1996 | 326 | 0.090 |
Why?
|
Prescriptions | 2 | 2023 | 387 | 0.090 |
Why?
|
Republic of Korea | 1 | 2011 | 539 | 0.090 |
Why?
|
General Practitioners | 1 | 2011 | 103 | 0.090 |
Why?
|
Paroxetine | 3 | 2000 | 182 | 0.090 |
Why?
|
Behavior Therapy | 2 | 2012 | 865 | 0.090 |
Why?
|
Canada | 2 | 2014 | 2065 | 0.090 |
Why?
|
Neurosciences | 1 | 2014 | 348 | 0.090 |
Why?
|
Referral and Consultation | 1 | 2002 | 3528 | 0.090 |
Why?
|
Neutropenia | 1 | 2015 | 895 | 0.090 |
Why?
|
Hypnotics and Sedatives | 3 | 2007 | 1162 | 0.090 |
Why?
|
Chemical Phenomena | 8 | 2002 | 518 | 0.090 |
Why?
|
Psychiatric Department, Hospital | 1 | 2010 | 135 | 0.090 |
Why?
|
Residence Characteristics | 2 | 2011 | 2050 | 0.090 |
Why?
|
Drug Resistance | 1 | 2015 | 1609 | 0.090 |
Why?
|
Physostigmine | 3 | 1979 | 53 | 0.090 |
Why?
|
Medication Adherence | 1 | 2021 | 2063 | 0.090 |
Why?
|
Phototherapy | 1 | 2012 | 377 | 0.080 |
Why?
|
Single-Blind Method | 1 | 2013 | 1590 | 0.080 |
Why?
|
Disease Models, Animal | 6 | 2005 | 18029 | 0.080 |
Why?
|
Calcium Channel Blockers | 1 | 2012 | 690 | 0.080 |
Why?
|
Sexuality | 1 | 2011 | 174 | 0.080 |
Why?
|
Lactation | 2 | 2009 | 412 | 0.080 |
Why?
|
Translations | 3 | 2004 | 64 | 0.080 |
Why?
|
Indicators and Reagents | 6 | 2006 | 462 | 0.080 |
Why?
|
Adenosine | 2 | 1990 | 825 | 0.080 |
Why?
|
Statistics as Topic | 2 | 2017 | 2373 | 0.080 |
Why?
|
Monoamine Oxidase | 6 | 1986 | 178 | 0.080 |
Why?
|
Tissue Distribution | 3 | 2006 | 2327 | 0.080 |
Why?
|
Psychomotor Performance | 2 | 2009 | 1901 | 0.080 |
Why?
|
Odds Ratio | 5 | 2009 | 9849 | 0.080 |
Why?
|
Health Services Accessibility | 1 | 2006 | 5137 | 0.080 |
Why?
|
Isotope Labeling | 2 | 2008 | 406 | 0.080 |
Why?
|
Decision Making | 1 | 2002 | 3887 | 0.080 |
Why?
|
Metabolic Clearance Rate | 4 | 2005 | 380 | 0.080 |
Why?
|
Reserpine | 7 | 1994 | 66 | 0.080 |
Why?
|
Electroencephalography | 3 | 2008 | 6150 | 0.080 |
Why?
|
Tyrosine | 7 | 1990 | 1461 | 0.080 |
Why?
|
Organ Specificity | 4 | 1998 | 2008 | 0.080 |
Why?
|
Half-Life | 6 | 1993 | 661 | 0.080 |
Why?
|
Microinjections | 3 | 1998 | 327 | 0.080 |
Why?
|
Health Care Costs | 2 | 2016 | 3209 | 0.080 |
Why?
|
Heart Rate | 3 | 2015 | 4091 | 0.080 |
Why?
|
Diagnosis, Dual (Psychiatry) | 2 | 2005 | 295 | 0.080 |
Why?
|
Patient Care Planning | 1 | 2013 | 921 | 0.080 |
Why?
|
Receptor, Serotonin, 5-HT2C | 3 | 2002 | 44 | 0.080 |
Why?
|
Carbohydrates | 1 | 2010 | 394 | 0.080 |
Why?
|
Artificial Intelligence | 1 | 2021 | 2214 | 0.080 |
Why?
|
Chemistry | 7 | 1990 | 352 | 0.080 |
Why?
|
Alkylation | 4 | 2004 | 86 | 0.080 |
Why?
|
Endocrine System Diseases | 1 | 2009 | 248 | 0.080 |
Why?
|
Body Weight | 4 | 2007 | 4669 | 0.080 |
Why?
|
Aftercare | 1 | 2013 | 866 | 0.080 |
Why?
|
Social Adjustment | 1 | 2010 | 631 | 0.080 |
Why?
|
Tomography, Emission-Computed | 3 | 2002 | 1144 | 0.070 |
Why?
|
Confidence Intervals | 3 | 2006 | 2971 | 0.070 |
Why?
|
Pituitary-Adrenal System | 2 | 2015 | 553 | 0.070 |
Why?
|
Cattle | 14 | 1990 | 3922 | 0.070 |
Why?
|
Natriuretic Peptide, Brain | 1 | 2015 | 1573 | 0.070 |
Why?
|
Neurotransmitter Transport Proteins | 1 | 2006 | 3 | 0.070 |
Why?
|
Medical Records Systems, Computerized | 1 | 2013 | 1205 | 0.070 |
Why?
|
Aged, 80 and over | 9 | 2011 | 57776 | 0.070 |
Why?
|
Organometallic Compounds | 2 | 2002 | 665 | 0.070 |
Why?
|
Patient Acceptance of Health Care | 1 | 2001 | 3022 | 0.070 |
Why?
|
Gene Expression Regulation, Developmental | 1 | 1998 | 3617 | 0.070 |
Why?
|
Microspheres | 1 | 2010 | 777 | 0.070 |
Why?
|
Neurons | 7 | 2006 | 9338 | 0.070 |
Why?
|
Octopamine | 5 | 1972 | 40 | 0.070 |
Why?
|
Cations | 1 | 1987 | 232 | 0.070 |
Why?
|
Liver | 18 | 1988 | 7474 | 0.070 |
Why?
|
Patient Education as Topic | 2 | 2014 | 2278 | 0.070 |
Why?
|
Radioimmunoassay | 5 | 1994 | 919 | 0.070 |
Why?
|
Emigrants and Immigrants | 1 | 2013 | 522 | 0.070 |
Why?
|
Proportional Hazards Models | 3 | 2010 | 12354 | 0.070 |
Why?
|
Cross Infection | 1 | 2016 | 1416 | 0.070 |
Why?
|
Dextroamphetamine | 4 | 1988 | 129 | 0.070 |
Why?
|
Databases as Topic | 1 | 2008 | 475 | 0.070 |
Why?
|
Cost-Benefit Analysis | 2 | 2014 | 5391 | 0.070 |
Why?
|
Citalopram | 1 | 2009 | 403 | 0.070 |
Why?
|
Alcoholic Intoxication | 1 | 2007 | 188 | 0.070 |
Why?
|
Ambulatory Care | 6 | 2003 | 2708 | 0.070 |
Why?
|
United States Food and Drug Administration | 3 | 2009 | 1584 | 0.070 |
Why?
|
Infusions, Intravenous | 3 | 2009 | 2274 | 0.070 |
Why?
|
Fertility | 1 | 2011 | 781 | 0.070 |
Why?
|
MEDLINE | 3 | 1995 | 125 | 0.070 |
Why?
|
Population Density | 1 | 2006 | 196 | 0.070 |
Why?
|
Delivery of Health Care | 2 | 2006 | 5319 | 0.070 |
Why?
|
Depression, Postpartum | 1 | 2010 | 340 | 0.070 |
Why?
|
Mathematical Computing | 1 | 2005 | 147 | 0.070 |
Why?
|
Cerebrovascular Disorders | 3 | 1987 | 1504 | 0.060 |
Why?
|
Models, Theoretical | 1 | 2017 | 3589 | 0.060 |
Why?
|
Parasympathomimetics | 1 | 1984 | 26 | 0.060 |
Why?
|
Internationality | 1 | 2011 | 1003 | 0.060 |
Why?
|
Mortality | 1 | 2017 | 2864 | 0.060 |
Why?
|
Sulfur | 1 | 2005 | 166 | 0.060 |
Why?
|
Histamine | 5 | 1975 | 507 | 0.060 |
Why?
|
Receptors, Adrenergic | 4 | 1988 | 155 | 0.060 |
Why?
|
Safety | 1 | 2010 | 1186 | 0.060 |
Why?
|
Tyramine | 5 | 1997 | 52 | 0.060 |
Why?
|
Dietary Supplements | 1 | 2018 | 3297 | 0.060 |
Why?
|
Actigraphy | 2 | 2023 | 488 | 0.060 |
Why?
|
Peer Review | 1 | 2007 | 209 | 0.060 |
Why?
|
Drug Administration Routes | 1 | 2005 | 153 | 0.060 |
Why?
|
Seasons | 3 | 2007 | 1493 | 0.060 |
Why?
|
Portacaval Shunt, Surgical | 4 | 1980 | 49 | 0.060 |
Why?
|
Censuses | 1 | 2006 | 200 | 0.060 |
Why?
|
Molecular Conformation | 7 | 1994 | 563 | 0.060 |
Why?
|
Locomotion | 2 | 1986 | 378 | 0.060 |
Why?
|
Indoles | 4 | 1997 | 1839 | 0.060 |
Why?
|
Parvalbumins | 1 | 2006 | 250 | 0.060 |
Why?
|
Corticosterone | 2 | 1985 | 310 | 0.060 |
Why?
|
Manganese | 2 | 1999 | 408 | 0.060 |
Why?
|
Drug Discovery | 1 | 2013 | 1058 | 0.060 |
Why?
|
Serotonin Antagonists | 2 | 2002 | 144 | 0.060 |
Why?
|
Pulse | 1 | 2004 | 229 | 0.060 |
Why?
|
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine | 5 | 1988 | 96 | 0.060 |
Why?
|
Sensitivity and Specificity | 3 | 2015 | 14722 | 0.060 |
Why?
|
Scopolamine | 2 | 1984 | 99 | 0.060 |
Why?
|
Child, Preschool | 8 | 2017 | 41006 | 0.060 |
Why?
|
Executive Function | 2 | 2010 | 1364 | 0.060 |
Why?
|
Regression Analysis | 4 | 2010 | 6459 | 0.060 |
Why?
|
Deep Brain Stimulation | 1 | 2012 | 748 | 0.060 |
Why?
|
Receptors, Cell Surface | 1 | 1994 | 2866 | 0.060 |
Why?
|
Psychoses, Substance-Induced | 4 | 1975 | 96 | 0.060 |
Why?
|
Propylamines | 1 | 2005 | 165 | 0.060 |
Why?
|
Aminopyridines | 2 | 1999 | 542 | 0.060 |
Why?
|
Legislation, Drug | 1 | 1986 | 206 | 0.060 |
Why?
|
Fenclonine | 4 | 1980 | 16 | 0.060 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2006 | 629 | 0.060 |
Why?
|
Adaptation, Psychological | 1 | 2014 | 2576 | 0.060 |
Why?
|
Cricetinae | 3 | 2003 | 2472 | 0.060 |
Why?
|
Insurance Claim Review | 1 | 2008 | 720 | 0.060 |
Why?
|
Language | 1 | 2013 | 1471 | 0.060 |
Why?
|
Up-Regulation | 2 | 2004 | 4217 | 0.060 |
Why?
|
Rehabilitation, Vocational | 1 | 2003 | 82 | 0.060 |
Why?
|
Adoption | 1 | 2004 | 97 | 0.060 |
Why?
|
C-Reactive Protein | 1 | 2015 | 3778 | 0.060 |
Why?
|
Bromocriptine | 3 | 1989 | 111 | 0.060 |
Why?
|
Phenoxybenzamine | 3 | 1980 | 54 | 0.060 |
Why?
|
Schizophrenia, Childhood | 1 | 2003 | 6 | 0.060 |
Why?
|
Factor Analysis, Statistical | 1 | 2006 | 977 | 0.060 |
Why?
|
Morpholines | 1 | 2006 | 571 | 0.060 |
Why?
|
Informed Consent | 3 | 1999 | 995 | 0.060 |
Why?
|
Brain Mapping | 3 | 1997 | 6669 | 0.060 |
Why?
|
Binding Sites | 7 | 1999 | 6114 | 0.060 |
Why?
|
History, Medieval | 2 | 2013 | 63 | 0.060 |
Why?
|
Principal Component Analysis | 1 | 2006 | 940 | 0.060 |
Why?
|
Blood Pressure | 3 | 2006 | 8554 | 0.060 |
Why?
|
Protein Binding | 5 | 2008 | 9386 | 0.060 |
Why?
|
Rats, Inbred SHR | 1 | 2003 | 195 | 0.060 |
Why?
|
Pregnant Women | 1 | 2008 | 568 | 0.060 |
Why?
|
CHO Cells | 2 | 2003 | 1406 | 0.060 |
Why?
|
Hyperandrogenism | 1 | 2003 | 38 | 0.060 |
Why?
|
Metabolic Diseases | 1 | 2009 | 658 | 0.050 |
Why?
|
Conditioning, Operant | 1 | 2004 | 313 | 0.050 |
Why?
|
Diet, Reducing | 1 | 2006 | 462 | 0.050 |
Why?
|
Echocardiography | 1 | 2015 | 5102 | 0.050 |
Why?
|
Receptors, Serotonin, 5-HT1 | 1 | 2002 | 13 | 0.050 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2006 | 841 | 0.050 |
Why?
|
Transcranial Magnetic Stimulation | 1 | 2012 | 1432 | 0.050 |
Why?
|
Ketanserin | 1 | 2002 | 24 | 0.050 |
Why?
|
Spectrophotometry, Ultraviolet | 4 | 2003 | 220 | 0.050 |
Why?
|
Basal Ganglia | 5 | 1980 | 546 | 0.050 |
Why?
|
Patient Selection | 2 | 2008 | 4215 | 0.050 |
Why?
|
N,N-Dimethyltryptamine | 2 | 1979 | 4 | 0.050 |
Why?
|
Cell Membrane | 8 | 2005 | 3748 | 0.050 |
Why?
|
Receptors, Adrenergic, beta | 2 | 1981 | 246 | 0.050 |
Why?
|
Health Care Surveys | 1 | 2010 | 2453 | 0.050 |
Why?
|
Financing, Government | 1 | 2006 | 468 | 0.050 |
Why?
|
Models, Psychological | 2 | 2004 | 811 | 0.050 |
Why?
|
Specialization | 1 | 2007 | 777 | 0.050 |
Why?
|
Nitric Oxide Synthase Type I | 1 | 2002 | 170 | 0.050 |
Why?
|
Indians, North American | 1 | 2006 | 355 | 0.050 |
Why?
|
Drug Design | 4 | 2015 | 1076 | 0.050 |
Why?
|
Sex Characteristics | 2 | 2011 | 2585 | 0.050 |
Why?
|
Twins | 1 | 2004 | 339 | 0.050 |
Why?
|
Milk, Human | 1 | 2007 | 490 | 0.050 |
Why?
|
Dosage Forms | 1 | 2002 | 56 | 0.050 |
Why?
|
Electrocardiography, Ambulatory | 2 | 1996 | 585 | 0.050 |
Why?
|
Nucleosides | 3 | 1970 | 138 | 0.050 |
Why?
|
Drug Screening Assays, Antitumor | 1 | 2004 | 730 | 0.050 |
Why?
|
Bioethics | 1 | 2003 | 116 | 0.050 |
Why?
|
Epidemiologic Studies | 1 | 2005 | 676 | 0.050 |
Why?
|
Isomerism | 5 | 1997 | 201 | 0.050 |
Why?
|
Managed Care Programs | 1 | 2007 | 950 | 0.050 |
Why?
|
History, 21st Century | 1 | 2008 | 1534 | 0.050 |
Why?
|
Accidents, Traffic | 1 | 2007 | 819 | 0.050 |
Why?
|
Pyrrolidines | 1 | 2003 | 342 | 0.050 |
Why?
|
Syndrome | 5 | 2000 | 3251 | 0.050 |
Why?
|
Polysomnography | 1 | 2008 | 1776 | 0.050 |
Why?
|
Cerebellar Cortex | 1 | 2002 | 107 | 0.050 |
Why?
|
Biological Transport | 4 | 2004 | 2118 | 0.050 |
Why?
|
Sodium | 6 | 1989 | 1623 | 0.050 |
Why?
|
Infusion Pumps | 1 | 2002 | 163 | 0.050 |
Why?
|
Parkinson Disease, Secondary | 2 | 1998 | 126 | 0.050 |
Why?
|
Practice Guidelines as Topic | 3 | 2019 | 7279 | 0.050 |
Why?
|
Levodopa | 5 | 1984 | 219 | 0.050 |
Why?
|
Product Surveillance, Postmarketing | 1 | 2005 | 430 | 0.050 |
Why?
|
Amitriptyline | 4 | 1985 | 110 | 0.050 |
Why?
|
Asia, Western | 1 | 2020 | 20 | 0.050 |
Why?
|
Metaraminol | 4 | 1974 | 8 | 0.050 |
Why?
|
Catechols | 4 | 1973 | 61 | 0.050 |
Why?
|
Models, Chemical | 3 | 2008 | 626 | 0.050 |
Why?
|
Body Mass Index | 3 | 2014 | 12720 | 0.050 |
Why?
|
1-Naphthylamine | 2 | 1997 | 49 | 0.050 |
Why?
|
Asia, Southeastern | 1 | 2020 | 111 | 0.050 |
Why?
|
Isoxazoles | 1 | 2002 | 216 | 0.050 |
Why?
|
Sulfur Radioisotopes | 1 | 2000 | 116 | 0.050 |
Why?
|
Subcellular Fractions | 6 | 1988 | 547 | 0.050 |
Why?
|
Medically Uninsured | 1 | 2006 | 853 | 0.050 |
Why?
|
Guanosine 5'-O-(3-Thiotriphosphate) | 1 | 2000 | 87 | 0.050 |
Why?
|
Carbon Isotopes | 9 | 1973 | 467 | 0.040 |
Why?
|
Mice | 17 | 2006 | 81183 | 0.040 |
Why?
|
Receptors, Cholinergic | 1 | 1980 | 238 | 0.040 |
Why?
|
Image Processing, Computer-Assisted | 4 | 2006 | 8949 | 0.040 |
Why?
|
Methylation | 7 | 1979 | 1106 | 0.040 |
Why?
|
Muscimol | 1 | 1979 | 69 | 0.040 |
Why?
|
Models, Statistical | 2 | 2016 | 5102 | 0.040 |
Why?
|
Multiple Sclerosis | 1 | 2014 | 3079 | 0.040 |
Why?
|
Baclofen | 1 | 2000 | 129 | 0.040 |
Why?
|
Receptors, Dopamine D5 | 1 | 1998 | 32 | 0.040 |
Why?
|
Women's Health | 1 | 2009 | 2034 | 0.040 |
Why?
|
Water Intoxication | 1 | 1998 | 11 | 0.040 |
Why?
|
Cohort Studies | 6 | 2016 | 40561 | 0.040 |
Why?
|
Guinea Pigs | 7 | 1997 | 1386 | 0.040 |
Why?
|
Synapses | 5 | 1979 | 1728 | 0.040 |
Why?
|
Medicine | 1 | 2007 | 946 | 0.040 |
Why?
|
Physicians | 2 | 2008 | 4567 | 0.040 |
Why?
|
Paranoid Disorders | 2 | 1992 | 60 | 0.040 |
Why?
|
Cycloheximide | 1 | 1978 | 347 | 0.040 |
Why?
|
Breast Feeding | 1 | 2007 | 1338 | 0.040 |
Why?
|
Excitatory Amino Acid Agonists | 1 | 1998 | 146 | 0.040 |
Why?
|
Attention | 2 | 2010 | 2400 | 0.040 |
Why?
|
Papio | 3 | 2008 | 656 | 0.040 |
Why?
|
Case-Control Studies | 3 | 2018 | 21746 | 0.040 |
Why?
|
Counseling | 1 | 2006 | 1523 | 0.040 |
Why?
|
Potassium | 5 | 1974 | 1336 | 0.040 |
Why?
|
Ethics | 1 | 1998 | 94 | 0.040 |
Why?
|
Neuroblastoma | 2 | 2005 | 1226 | 0.040 |
Why?
|
Hospitals, Teaching | 2 | 2001 | 1179 | 0.040 |
Why?
|
Oxazoles | 1 | 1979 | 189 | 0.040 |
Why?
|
Textbooks as Topic | 2 | 2011 | 19 | 0.040 |
Why?
|
Pyrroles | 1 | 2004 | 1146 | 0.040 |
Why?
|
Health Services Needs and Demand | 1 | 2006 | 1411 | 0.040 |
Why?
|
Exercise | 2 | 2022 | 5615 | 0.040 |
Why?
|
Water-Electrolyte Imbalance | 1 | 1998 | 113 | 0.040 |
Why?
|
Clinical Laboratory Techniques | 1 | 1983 | 738 | 0.040 |
Why?
|
Parkinsonian Disorders | 1 | 2000 | 275 | 0.040 |
Why?
|
Reality Testing | 1 | 2017 | 26 | 0.040 |
Why?
|
Program Evaluation | 1 | 2006 | 2488 | 0.040 |
Why?
|
Consensus | 2 | 2019 | 2959 | 0.040 |
Why?
|
Salicylamides | 2 | 1994 | 33 | 0.040 |
Why?
|
Receptors, Neurotransmitter | 2 | 1994 | 178 | 0.040 |
Why?
|
Electronic Health Records | 2 | 2014 | 4468 | 0.040 |
Why?
|
Temperature | 8 | 1978 | 2206 | 0.040 |
Why?
|
Clinical Medicine | 1 | 1999 | 147 | 0.040 |
Why?
|
Fluvoxamine | 1 | 1997 | 74 | 0.040 |
Why?
|
Infant | 2 | 2017 | 35136 | 0.040 |
Why?
|
Analgesics, Opioid | 1 | 2013 | 3674 | 0.040 |
Why?
|
Depression, Chemical | 5 | 1978 | 191 | 0.040 |
Why?
|
Family | 2 | 2009 | 3147 | 0.040 |
Why?
|
Cerebellum | 3 | 1979 | 1488 | 0.040 |
Why?
|
Income | 1 | 2006 | 1913 | 0.040 |
Why?
|
Quality of Life | 2 | 2015 | 12804 | 0.040 |
Why?
|
Genetic Predisposition to Disease | 1 | 2018 | 17446 | 0.040 |
Why?
|
Hydrazines | 3 | 1994 | 226 | 0.040 |
Why?
|
Amino Acids | 4 | 1977 | 1736 | 0.040 |
Why?
|
Reference Values | 4 | 1993 | 4982 | 0.040 |
Why?
|
Sucrose | 1 | 1977 | 164 | 0.040 |
Why?
|
Hydroxydopamines | 4 | 1990 | 59 | 0.040 |
Why?
|
Electrocardiography | 2 | 2004 | 6442 | 0.040 |
Why?
|
Spectrometry, Mass, Fast Atom Bombardment | 1 | 1996 | 31 | 0.040 |
Why?
|
Brain Diseases | 1 | 1986 | 1563 | 0.030 |
Why?
|
Models, Animal | 1 | 2003 | 2171 | 0.030 |
Why?
|
Sulpiride | 1 | 1995 | 17 | 0.030 |
Why?
|
Lipid Metabolism | 1 | 1985 | 1889 | 0.030 |
Why?
|
Methyldopa | 2 | 1972 | 20 | 0.030 |
Why?
|
L-Lactate Dehydrogenase | 1 | 1977 | 424 | 0.030 |
Why?
|
Electric Stimulation | 6 | 1988 | 1767 | 0.030 |
Why?
|
Magnetic Resonance Spectroscopy | 3 | 2002 | 3760 | 0.030 |
Why?
|
Blepharoptosis | 3 | 1982 | 143 | 0.030 |
Why?
|
Chemistry, Pharmaceutical | 2 | 2008 | 281 | 0.030 |
Why?
|
Quinuclidinyl Benzilate | 3 | 1988 | 19 | 0.030 |
Why?
|
Hospital Bed Capacity | 1 | 1997 | 214 | 0.030 |
Why?
|
Blood Glucose | 2 | 2014 | 6256 | 0.030 |
Why?
|
Pyrogallol | 5 | 1975 | 8 | 0.030 |
Why?
|
Hyponatremia | 1 | 1998 | 298 | 0.030 |
Why?
|
Pyrazines | 1 | 2001 | 1230 | 0.030 |
Why?
|
Cholesterol | 1 | 2004 | 2917 | 0.030 |
Why?
|
Career Mobility | 1 | 1998 | 262 | 0.030 |
Why?
|
Stereotaxic Techniques | 1 | 1997 | 536 | 0.030 |
Why?
|
Butyrophenones | 4 | 1992 | 16 | 0.030 |
Why?
|
Thermodynamics | 2 | 1987 | 596 | 0.030 |
Why?
|
Data Interpretation, Statistical | 1 | 2005 | 2716 | 0.030 |
Why?
|
Calcium | 6 | 1981 | 5756 | 0.030 |
Why?
|
Amantadine | 2 | 1972 | 55 | 0.030 |
Why?
|
Myocardium | 9 | 1973 | 4776 | 0.030 |
Why?
|
Neurofibrillary Tangles | 1 | 1997 | 439 | 0.030 |
Why?
|
Health Policy | 1 | 2007 | 2661 | 0.030 |
Why?
|
Remission Induction | 1 | 2000 | 2386 | 0.030 |
Why?
|
Homocystinuria | 1 | 1975 | 67 | 0.030 |
Why?
|
Mass Spectrometry | 2 | 1993 | 2203 | 0.030 |
Why?
|
RNA, Messenger | 3 | 2005 | 13033 | 0.030 |
Why?
|
Ohio | 1 | 2015 | 337 | 0.030 |
Why?
|
Biochemical Phenomena | 2 | 1965 | 59 | 0.030 |
Why?
|
Memory | 1 | 2004 | 2174 | 0.030 |
Why?
|
Adrenal Cortex | 1 | 2015 | 140 | 0.030 |
Why?
|
Adrenal Glands | 3 | 1966 | 546 | 0.030 |
Why?
|
4-Butyrolactone | 1 | 1994 | 63 | 0.030 |
Why?
|
Movement | 2 | 1978 | 1471 | 0.030 |
Why?
|
Glutamic Acid | 1 | 2000 | 1169 | 0.030 |
Why?
|
Self Disclosure | 1 | 2015 | 251 | 0.030 |
Why?
|
Biochemistry | 2 | 1965 | 113 | 0.030 |
Why?
|
Carbon Radioisotopes | 4 | 1984 | 577 | 0.030 |
Why?
|
Blood-Brain Barrier | 3 | 2006 | 1017 | 0.030 |
Why?
|
Autopsy | 1 | 1997 | 1020 | 0.030 |
Why?
|
Ethics, Medical | 1 | 1999 | 792 | 0.030 |
Why?
|
History, 15th Century | 1 | 2012 | 31 | 0.030 |
Why?
|
Calcium-Binding Proteins | 1 | 1998 | 1081 | 0.030 |
Why?
|
Seasonal Affective Disorder | 1 | 1993 | 50 | 0.030 |
Why?
|
Crime | 1 | 2014 | 215 | 0.030 |
Why?
|
Drug Evaluation, Preclinical | 3 | 2005 | 1375 | 0.030 |
Why?
|
Ouabain | 4 | 1974 | 264 | 0.030 |
Why?
|
London | 1 | 2012 | 233 | 0.030 |
Why?
|
Models, Genetic | 1 | 2003 | 3494 | 0.030 |
Why?
|
Cytoplasm | 1 | 1977 | 1539 | 0.030 |
Why?
|
Mice, Knockout | 2 | 2004 | 14557 | 0.030 |
Why?
|
Leukemia, Myeloid | 2 | 1966 | 707 | 0.030 |
Why?
|
Affinity Labels | 1 | 1992 | 109 | 0.030 |
Why?
|
Phenanthridines | 1 | 1991 | 51 | 0.030 |
Why?
|
Frontal Lobe | 1 | 1999 | 1406 | 0.030 |
Why?
|
Quinpirole | 1 | 1991 | 33 | 0.030 |
Why?
|
Phenazocine | 1 | 1991 | 7 | 0.030 |
Why?
|
Cyclazocine | 1 | 1991 | 10 | 0.030 |
Why?
|
Impulsive Behavior | 1 | 2014 | 316 | 0.030 |
Why?
|
Chromatography, Thin Layer | 3 | 2002 | 223 | 0.030 |
Why?
|
Pentazocine | 1 | 1991 | 13 | 0.030 |
Why?
|
Health Education | 1 | 1999 | 1056 | 0.030 |
Why?
|
Injections, Intraventricular | 3 | 1988 | 230 | 0.030 |
Why?
|
Benserazide | 3 | 1976 | 5 | 0.030 |
Why?
|
Georgia | 1 | 2011 | 186 | 0.030 |
Why?
|
Hospitals, General | 1 | 2016 | 749 | 0.030 |
Why?
|
Transferases | 3 | 1972 | 75 | 0.030 |
Why?
|
Diencephalon | 2 | 1986 | 56 | 0.020 |
Why?
|
Pyrimidines | 2 | 2001 | 2942 | 0.020 |
Why?
|
Monitoring, Physiologic | 1 | 1979 | 1738 | 0.020 |
Why?
|
2-Chloroadenosine | 1 | 1990 | 11 | 0.020 |
Why?
|
Biotin | 1 | 1992 | 254 | 0.020 |
Why?
|
Dystonia | 2 | 1988 | 363 | 0.020 |
Why?
|
8-Bromo Cyclic Adenosine Monophosphate | 1 | 1990 | 76 | 0.020 |
Why?
|
Electrochemistry | 2 | 1988 | 145 | 0.020 |
Why?
|
Telencephalon | 2 | 1986 | 142 | 0.020 |
Why?
|
Rabbits | 5 | 1984 | 4894 | 0.020 |
Why?
|
Phenylalanine | 1 | 1972 | 365 | 0.020 |
Why?
|
Theophylline | 1 | 1990 | 132 | 0.020 |
Why?
|
Cost Savings | 1 | 2016 | 926 | 0.020 |
Why?
|
Receptors, Purinergic | 1 | 1990 | 66 | 0.020 |
Why?
|
Catechol O-Methyltransferase | 3 | 1978 | 245 | 0.020 |
Why?
|
Hydrogen-Ion Concentration | 2 | 1976 | 2557 | 0.020 |
Why?
|
Isoproterenol | 2 | 1981 | 399 | 0.020 |
Why?
|
Cloning, Molecular | 1 | 1996 | 4320 | 0.020 |
Why?
|
Aorta | 1 | 1978 | 2061 | 0.020 |
Why?
|
Domperidone | 1 | 1989 | 23 | 0.020 |
Why?
|
Synaptic Membranes | 2 | 1982 | 91 | 0.020 |
Why?
|
Normetanephrine | 4 | 1973 | 26 | 0.020 |
Why?
|
Axons | 1 | 1998 | 1684 | 0.020 |
Why?
|
Seizures | 2 | 1979 | 2859 | 0.020 |
Why?
|
Chromatography, Liquid | 1 | 1993 | 976 | 0.020 |
Why?
|
Technetium | 2 | 2000 | 334 | 0.020 |
Why?
|
Echocardiography, Doppler | 1 | 1993 | 935 | 0.020 |
Why?
|
Brain Stem | 5 | 1979 | 846 | 0.020 |
Why?
|
Gene Expression | 1 | 2002 | 7799 | 0.020 |
Why?
|
Prenatal Exposure Delayed Effects | 1 | 1981 | 2408 | 0.020 |
Why?
|
Septal Nuclei | 1 | 1989 | 85 | 0.020 |
Why?
|
Phenols | 1 | 1973 | 497 | 0.020 |
Why?
|
5,6-Dihydroxytryptamine | 2 | 1980 | 5 | 0.020 |
Why?
|
p-Hydroxyamphetamine | 1 | 1988 | 3 | 0.020 |
Why?
|
Pyramidal Tracts | 1 | 1991 | 256 | 0.020 |
Why?
|
Veratridine | 1 | 1988 | 24 | 0.020 |
Why?
|
Neural Inhibition | 2 | 1987 | 602 | 0.020 |
Why?
|
Ambulatory Care Facilities | 1 | 2015 | 933 | 0.020 |
Why?
|
Hydroxylation | 3 | 1973 | 141 | 0.020 |
Why?
|
Positron-Emission Tomography | 1 | 2004 | 6234 | 0.020 |
Why?
|
Cytoplasmic Granules | 1 | 1971 | 610 | 0.020 |
Why?
|
Sympathetic Nervous System | 1 | 1971 | 514 | 0.020 |
Why?
|
Biomedical Research | 2 | 2003 | 3309 | 0.020 |
Why?
|
Tissue Donors | 1 | 2018 | 2240 | 0.020 |
Why?
|
Reproducibility of Results | 2 | 2016 | 19905 | 0.020 |
Why?
|
Activity Cycles | 1 | 1988 | 51 | 0.020 |
Why?
|
Pyridinium Compounds | 1 | 1988 | 84 | 0.020 |
Why?
|
Fibroblasts | 3 | 1993 | 4161 | 0.020 |
Why?
|
Antiparkinson Agents | 1 | 1988 | 184 | 0.020 |
Why?
|
Verbal Learning | 1 | 2010 | 467 | 0.020 |
Why?
|
Biotransformation | 2 | 2003 | 168 | 0.020 |
Why?
|
Lung | 4 | 1979 | 9856 | 0.020 |
Why?
|
Genetic Variation | 1 | 2003 | 6544 | 0.020 |
Why?
|
France | 1 | 2009 | 517 | 0.020 |
Why?
|
Leukocytes | 2 | 1966 | 2043 | 0.020 |
Why?
|
Probability | 3 | 1993 | 2505 | 0.020 |
Why?
|
Kidney | 5 | 1979 | 7186 | 0.020 |
Why?
|
Leukocyte Count | 2 | 1995 | 1588 | 0.020 |
Why?
|
Haplorhini | 3 | 1976 | 552 | 0.020 |
Why?
|
Cholesterol, HDL | 1 | 2014 | 1814 | 0.020 |
Why?
|
Hemodynamics | 2 | 1993 | 4199 | 0.020 |
Why?
|
Blood Urea Nitrogen | 1 | 2007 | 191 | 0.020 |
Why?
|
Tremor | 2 | 1979 | 175 | 0.020 |
Why?
|
Pineal Gland | 2 | 1972 | 166 | 0.020 |
Why?
|
Muridae | 1 | 1986 | 61 | 0.020 |
Why?
|
Alphaprodine | 1 | 1986 | 2 | 0.020 |
Why?
|
Infant, Newborn | 1 | 2007 | 25625 | 0.020 |
Why?
|
Gene Expression Regulation | 1 | 2005 | 12072 | 0.020 |
Why?
|
Postmortem Changes | 1 | 2006 | 126 | 0.020 |
Why?
|
Meperidine | 1 | 1986 | 38 | 0.020 |
Why?
|
Radioactive Tracers | 1 | 2006 | 72 | 0.020 |
Why?
|
Methysergide | 2 | 1976 | 28 | 0.020 |
Why?
|
Injections, Intraperitoneal | 4 | 1992 | 425 | 0.020 |
Why?
|
Anti-Anxiety Agents | 2 | 1993 | 390 | 0.020 |
Why?
|
Catatonia | 1 | 2009 | 158 | 0.020 |
Why?
|
Liver Diseases | 2 | 1971 | 1253 | 0.020 |
Why?
|
Macaca fascicularis | 1 | 1988 | 915 | 0.020 |
Why?
|
Triglycerides | 1 | 2014 | 2454 | 0.020 |
Why?
|
Models, Molecular | 2 | 1994 | 5456 | 0.020 |
Why?
|
Blood Platelets | 4 | 1985 | 2508 | 0.020 |
Why?
|
Personality Disorders | 1 | 2010 | 713 | 0.020 |
Why?
|
Cells, Cultured | 5 | 1994 | 19229 | 0.020 |
Why?
|
Salivary Glands | 1 | 1967 | 229 | 0.020 |
Why?
|
Light | 1 | 1992 | 1374 | 0.020 |
Why?
|
Intestine, Small | 1 | 1972 | 1241 | 0.020 |
Why?
|
Skin | 3 | 1978 | 4364 | 0.020 |
Why?
|
Transfection | 1 | 1993 | 5892 | 0.020 |
Why?
|
Antimetabolites | 1 | 1965 | 125 | 0.020 |
Why?
|
Pilocarpine | 1 | 1984 | 63 | 0.020 |
Why?
|
Child Abuse, Sexual | 1 | 2008 | 383 | 0.020 |
Why?
|
Biopharmaceutics | 1 | 1984 | 22 | 0.020 |
Why?
|
Membranes | 2 | 1997 | 173 | 0.020 |
Why?
|
Cats | 3 | 1972 | 998 | 0.020 |
Why?
|
Dominance, Cerebral | 2 | 1983 | 635 | 0.020 |
Why?
|
Gas Chromatography-Mass Spectrometry | 2 | 1988 | 361 | 0.020 |
Why?
|
Proadifen | 3 | 1987 | 11 | 0.020 |
Why?
|
Creatine | 1 | 2007 | 421 | 0.020 |
Why?
|
Pargyline | 3 | 1976 | 19 | 0.020 |
Why?
|
Maternal-Fetal Exchange | 1 | 2007 | 456 | 0.020 |
Why?
|
Promethazine | 2 | 1974 | 29 | 0.020 |
Why?
|
Kidney Function Tests | 1 | 2007 | 684 | 0.020 |
Why?
|
Chromatography, Ion Exchange | 3 | 1974 | 305 | 0.020 |
Why?
|
Drug Approval | 1 | 2011 | 742 | 0.020 |
Why?
|
Osmolar Concentration | 2 | 1977 | 683 | 0.020 |
Why?
|
Glutamates | 2 | 1976 | 398 | 0.020 |
Why?
|
Cholesterol, LDL | 1 | 2014 | 2356 | 0.020 |
Why?
|
Excitatory Amino Acid Agents | 1 | 2004 | 23 | 0.020 |
Why?
|
Butaclamol | 1 | 1983 | 5 | 0.010 |
Why?
|
Dinitrophenols | 2 | 1974 | 57 | 0.010 |
Why?
|
Trichloroacetic Acid | 1 | 1983 | 33 | 0.010 |
Why?
|
Phospholipids | 1 | 1987 | 784 | 0.010 |
Why?
|
Fluorescent Dyes | 1 | 1992 | 1917 | 0.010 |
Why?
|
Medulla Oblongata | 3 | 1974 | 243 | 0.010 |
Why?
|
Neural Pathways | 2 | 1991 | 2972 | 0.010 |
Why?
|
Cooperative Behavior | 1 | 2011 | 1504 | 0.010 |
Why?
|
Phenobarbital | 2 | 1974 | 193 | 0.010 |
Why?
|
Methoxyhydroxyphenylglycol | 2 | 1990 | 93 | 0.010 |
Why?
|
Chemistry Techniques, Analytical | 1 | 1963 | 49 | 0.010 |
Why?
|
Diazepam | 2 | 1974 | 205 | 0.010 |
Why?
|
Centrifugation, Density Gradient | 2 | 1974 | 313 | 0.010 |
Why?
|
Muscle Contraction | 2 | 1978 | 1240 | 0.010 |
Why?
|
Arrhythmias, Cardiac | 1 | 1993 | 2268 | 0.010 |
Why?
|
Thyrotropin | 1 | 2007 | 849 | 0.010 |
Why?
|
Hypothalamus | 4 | 1973 | 1063 | 0.010 |
Why?
|
Blotting, Northern | 1 | 2005 | 1581 | 0.010 |
Why?
|
Kidney Diseases | 4 | 1978 | 2149 | 0.010 |
Why?
|
Biological Availability | 2 | 1980 | 397 | 0.010 |
Why?
|
Memory Disorders | 1 | 2010 | 1184 | 0.010 |
Why?
|
Patient Readmission | 1 | 1997 | 3114 | 0.010 |
Why?
|
Internship and Residency | 1 | 2003 | 5788 | 0.010 |
Why?
|
Leukemia | 2 | 1975 | 1511 | 0.010 |
Why?
|
Intestines | 1 | 1972 | 1924 | 0.010 |
Why?
|
Intensive Care Units | 1 | 2016 | 3679 | 0.010 |
Why?
|
Evaluation Studies as Topic | 1 | 1985 | 1681 | 0.010 |
Why?
|
Human Experimentation | 1 | 2003 | 127 | 0.010 |
Why?
|
Receptors, Adrenergic, alpha-1 | 1 | 2002 | 47 | 0.010 |
Why?
|
Vitamin B 12 | 1 | 1965 | 527 | 0.010 |
Why?
|
Receptors, Adrenergic, alpha-2 | 1 | 2002 | 64 | 0.010 |
Why?
|
Cerebral Ventricles | 1 | 1985 | 544 | 0.010 |
Why?
|
Cell Count | 1 | 2006 | 1856 | 0.010 |
Why?
|
Clonidine | 1 | 1983 | 164 | 0.010 |
Why?
|
Chemistry, Physical | 1 | 2002 | 156 | 0.010 |
Why?
|
Trifluoperazine | 1 | 1981 | 40 | 0.010 |
Why?
|
Edetic Acid | 1 | 1982 | 276 | 0.010 |
Why?
|
Cardiovascular System | 1 | 1989 | 832 | 0.010 |
Why?
|
False Negative Reactions | 1 | 1983 | 588 | 0.010 |
Why?
|
Psychology | 1 | 2004 | 356 | 0.010 |
Why?
|
Phenylacetates | 2 | 1972 | 114 | 0.010 |
Why?
|
Spleen | 3 | 1966 | 2362 | 0.010 |
Why?
|
Cell Aggregation | 1 | 1981 | 244 | 0.010 |
Why?
|
Sleep, REM | 1 | 1985 | 595 | 0.010 |
Why?
|
p-Chloroamphetamine | 1 | 1980 | 7 | 0.010 |
Why?
|
Locus Coeruleus | 1 | 2002 | 176 | 0.010 |
Why?
|
Signal Transduction | 1 | 2004 | 23403 | 0.010 |
Why?
|
Propranolol | 1 | 1983 | 502 | 0.010 |
Why?
|
Hypertension | 2 | 1978 | 8480 | 0.010 |
Why?
|
Doxepin | 2 | 1983 | 16 | 0.010 |
Why?
|
Periodicals as Topic | 1 | 1992 | 1432 | 0.010 |
Why?
|
Carbonates | 2 | 1970 | 21 | 0.010 |
Why?
|
Biological Assay | 1 | 1984 | 652 | 0.010 |
Why?
|
In Situ Hybridization | 1 | 2005 | 1950 | 0.010 |
Why?
|
False Positive Reactions | 1 | 1983 | 981 | 0.010 |
Why?
|
Raphe Nuclei | 1 | 1980 | 104 | 0.010 |
Why?
|
Alprenolol | 1 | 1979 | 8 | 0.010 |
Why?
|
Remission, Spontaneous | 1 | 1980 | 382 | 0.010 |
Why?
|
1-Methyl-3-isobutylxanthine | 1 | 1979 | 102 | 0.010 |
Why?
|
COS Cells | 1 | 2002 | 1161 | 0.010 |
Why?
|
Protein Transport | 1 | 2005 | 1988 | 0.010 |
Why?
|
Urea | 2 | 1972 | 450 | 0.010 |
Why?
|
Cyproheptadine | 1 | 1979 | 21 | 0.010 |
Why?
|
Growth | 1 | 1981 | 376 | 0.010 |
Why?
|
Electronics, Medical | 1 | 1979 | 71 | 0.010 |
Why?
|
Ascorbic Acid | 1 | 1982 | 651 | 0.010 |
Why?
|
Epidemiologic Methods | 1 | 1984 | 1364 | 0.010 |
Why?
|
Area Under Curve | 1 | 2003 | 1654 | 0.010 |
Why?
|
Olfactory Bulb | 2 | 1985 | 200 | 0.010 |
Why?
|
Chromatography, Paper | 2 | 1974 | 77 | 0.010 |
Why?
|
Bucladesine | 2 | 1975 | 121 | 0.010 |
Why?
|
Poisoning | 1 | 1979 | 249 | 0.010 |
Why?
|
Tranylcypromine | 2 | 1988 | 29 | 0.010 |
Why?
|
Premedication | 1 | 1978 | 258 | 0.010 |
Why?
|
Dopamine Uptake Inhibitors | 1 | 1999 | 312 | 0.010 |
Why?
|
Type C Phospholipases | 1 | 1998 | 292 | 0.010 |
Why?
|
Lymphocytes | 1 | 1965 | 2617 | 0.010 |
Why?
|
Glycine | 2 | 1974 | 671 | 0.010 |
Why?
|
Dementia | 2 | 1986 | 2518 | 0.010 |
Why?
|
Blotting, Western | 1 | 2005 | 5179 | 0.010 |
Why?
|
Adaptation, Physiological | 1 | 2004 | 1312 | 0.010 |
Why?
|
Spinal Cord | 3 | 1974 | 1809 | 0.010 |
Why?
|
Phenelzine | 2 | 1988 | 28 | 0.010 |
Why?
|
Cell Fractionation | 1 | 1977 | 252 | 0.010 |
Why?
|
Anorexia Nervosa | 1 | 1986 | 1286 | 0.010 |
Why?
|
Lysergic Acid Diethylamide | 1 | 1976 | 48 | 0.010 |
Why?
|
Cations, Divalent | 1 | 1976 | 166 | 0.010 |
Why?
|
Mouth | 1 | 1979 | 374 | 0.010 |
Why?
|
Neuromuscular Junction | 1 | 1978 | 398 | 0.010 |
Why?
|
Hydrolysis | 1 | 1977 | 682 | 0.010 |
Why?
|
Iproniazid | 2 | 1966 | 8 | 0.010 |
Why?
|
Fluorides | 1 | 1976 | 127 | 0.010 |
Why?
|
Homocystine | 1 | 1975 | 22 | 0.010 |
Why?
|
Acetylserotonin O-Methyltransferase | 1 | 1975 | 3 | 0.010 |
Why?
|
Injections, Intramuscular | 1 | 1997 | 552 | 0.010 |
Why?
|
Tryptophan Hydroxylase | 1 | 1975 | 89 | 0.010 |
Why?
|
Goiter | 1 | 1975 | 87 | 0.010 |
Why?
|
Mitochondria | 3 | 1974 | 3520 | 0.010 |
Why?
|
Methionine Adenosyltransferase | 1 | 1975 | 17 | 0.010 |
Why?
|
Methyltyrosines | 1 | 1974 | 7 | 0.010 |
Why?
|
Spectrometry, Fluorescence | 1 | 1977 | 689 | 0.010 |
Why?
|
Electrophoresis, Paper | 1 | 1974 | 14 | 0.010 |
Why?
|
Mice, Inbred BALB C | 1 | 1984 | 6386 | 0.010 |
Why?
|
Substrate Specificity | 1 | 1979 | 1801 | 0.010 |
Why?
|
Ammonia | 1 | 1976 | 239 | 0.010 |
Why?
|
Tetrahydrofolates | 1 | 1975 | 61 | 0.010 |
Why?
|
Father-Child Relations | 1 | 1974 | 48 | 0.010 |
Why?
|
Fluorometry | 2 | 1972 | 106 | 0.010 |
Why?
|
Thiethylperazine | 1 | 1973 | 2 | 0.010 |
Why?
|
Tumor Cells, Cultured | 1 | 2002 | 6314 | 0.010 |
Why?
|
Injections, Intravenous | 2 | 1979 | 1420 | 0.010 |
Why?
|
Valinomycin | 1 | 1973 | 19 | 0.010 |
Why?
|
Gramicidin | 1 | 1973 | 12 | 0.010 |
Why?
|
Cesium | 1 | 1973 | 38 | 0.010 |
Why?
|
Brain Damage, Chronic | 1 | 1974 | 265 | 0.010 |
Why?
|
Picrotoxin | 1 | 1973 | 65 | 0.010 |
Why?
|
Rubidium | 1 | 1973 | 133 | 0.010 |
Why?
|
Aminolevulinic Acid | 1 | 1974 | 142 | 0.010 |
Why?
|
Muscle, Smooth | 1 | 1978 | 934 | 0.010 |
Why?
|
Portal System | 1 | 1973 | 52 | 0.010 |
Why?
|
Ephedrine | 1 | 1973 | 54 | 0.010 |
Why?
|
Xanthines | 1 | 1973 | 121 | 0.010 |
Why?
|
Cyclic GMP | 1 | 1974 | 409 | 0.010 |
Why?
|
Cholinesterase Inhibitors | 1 | 1975 | 238 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 2 | 2013 | 35421 | 0.010 |
Why?
|
Allosteric Regulation | 1 | 1974 | 408 | 0.010 |
Why?
|
Dioxoles | 1 | 1973 | 104 | 0.010 |
Why?
|
Rodentia | 1 | 1994 | 261 | 0.010 |
Why?
|
Amphetamines | 1 | 1974 | 148 | 0.010 |
Why?
|
Guanidines | 1 | 1993 | 193 | 0.010 |
Why?
|
Magnesium | 1 | 1976 | 813 | 0.010 |
Why?
|
Erythrocytes | 2 | 1979 | 2455 | 0.010 |
Why?
|
Mesencephalon | 1 | 1974 | 329 | 0.010 |
Why?
|
Sulfides | 1 | 1973 | 165 | 0.010 |
Why?
|
Immunohistochemistry | 1 | 2006 | 11366 | 0.010 |
Why?
|
Neurosecretion | 1 | 1972 | 11 | 0.010 |
Why?
|
Centrifugation | 1 | 1972 | 122 | 0.010 |
Why?
|
Phenylalanine Hydroxylase | 1 | 1972 | 30 | 0.010 |
Why?
|
Tetrodotoxin | 1 | 1973 | 259 | 0.010 |
Why?
|
Alkaloids | 1 | 1973 | 190 | 0.010 |
Why?
|
Reticular Formation | 1 | 1972 | 61 | 0.010 |
Why?
|
Deamination | 1 | 1972 | 26 | 0.010 |
Why?
|
Bacterial Toxins | 1 | 1998 | 931 | 0.010 |
Why?
|
Amine Oxidase (Copper-Containing) | 1 | 1972 | 41 | 0.010 |
Why?
|
Gastric Juice | 1 | 1972 | 63 | 0.010 |
Why?
|
Biological Transport, Active | 1 | 1972 | 349 | 0.010 |
Why?
|
Kanamycin | 1 | 1972 | 64 | 0.010 |
Why?
|
Aspartic Acid | 1 | 1974 | 576 | 0.010 |
Why?
|
Vanilmandelic Acid | 1 | 1971 | 17 | 0.010 |
Why?
|
Statistics, Nonparametric | 1 | 1998 | 2886 | 0.010 |
Why?
|
Chromatography, Gas | 1 | 1992 | 156 | 0.010 |
Why?
|
Carboxy-Lyases | 1 | 1972 | 90 | 0.010 |
Why?
|
Pons | 1 | 1973 | 245 | 0.010 |
Why?
|
Isoquinolines | 1 | 1973 | 367 | 0.010 |
Why?
|
Endocrine Glands | 1 | 1972 | 103 | 0.010 |
Why?
|
Histocytochemistry | 1 | 1973 | 719 | 0.010 |
Why?
|
Prostaglandins | 1 | 1973 | 405 | 0.010 |
Why?
|
Dialysis | 1 | 1971 | 75 | 0.010 |
Why?
|
Neurochemistry | 1 | 1971 | 29 | 0.010 |
Why?
|
Acetyltransferases | 1 | 1973 | 234 | 0.010 |
Why?
|
Life Tables | 1 | 1991 | 370 | 0.010 |
Why?
|
Glutamine | 1 | 1974 | 578 | 0.010 |
Why?
|
Propionates | 1 | 1972 | 169 | 0.010 |
Why?
|
Enzyme Inhibitors | 1 | 2002 | 3798 | 0.010 |
Why?
|
Estradiol | 1 | 1979 | 2020 | 0.010 |
Why?
|
Sexual Behavior, Animal | 1 | 1972 | 113 | 0.010 |
Why?
|
Choline | 1 | 1973 | 493 | 0.010 |
Why?
|
Histidine | 1 | 1972 | 313 | 0.010 |
Why?
|
Hypotension | 1 | 1997 | 884 | 0.010 |
Why?
|
Central Nervous System Diseases | 1 | 1975 | 518 | 0.010 |
Why?
|
Sterilization | 1 | 1972 | 133 | 0.010 |
Why?
|
Adrenal Medulla | 1 | 1970 | 58 | 0.010 |
Why?
|
Acetylcholine | 1 | 1973 | 621 | 0.010 |
Why?
|
Mother-Child Relations | 1 | 1974 | 481 | 0.010 |
Why?
|
Quality Control | 1 | 1993 | 841 | 0.010 |
Why?
|
Filtration | 1 | 1971 | 234 | 0.010 |
Why?
|
Autonomic Nervous System | 1 | 1975 | 671 | 0.010 |
Why?
|
Maryland | 1 | 1970 | 276 | 0.010 |
Why?
|
Benzoates | 1 | 1972 | 217 | 0.010 |
Why?
|
Stress Disorders, Post-Traumatic | 1 | 2008 | 4266 | 0.010 |
Why?
|
Synaptic Vesicles | 1 | 1971 | 191 | 0.010 |
Why?
|
Curriculum | 1 | 2003 | 3605 | 0.010 |
Why?
|
Stomach | 2 | 1972 | 697 | 0.010 |
Why?
|
Narcolepsy | 1 | 1972 | 195 | 0.010 |
Why?
|
Organ Culture Techniques | 1 | 1971 | 813 | 0.010 |
Why?
|
Carbon Dioxide | 1 | 1973 | 1150 | 0.010 |
Why?
|
Prazosin | 1 | 1988 | 96 | 0.010 |
Why?
|
Exercise Test | 1 | 1996 | 2074 | 0.010 |
Why?
|
Gastric Mucosa | 1 | 1972 | 599 | 0.010 |
Why?
|
Kidney Tubules | 1 | 1970 | 488 | 0.010 |
Why?
|
1-Methyl-4-phenylpyridinium | 1 | 1988 | 30 | 0.010 |
Why?
|
Perphenazine | 1 | 1988 | 34 | 0.000 |
Why?
|
Cell Line, Tumor | 1 | 2005 | 16689 | 0.000 |
Why?
|
Heart | 2 | 1972 | 4467 | 0.000 |
Why?
|
Nervous System | 1 | 1971 | 554 | 0.000 |
Why?
|
Heart Block | 1 | 1989 | 410 | 0.000 |
Why?
|
Regional Blood Flow | 1 | 1971 | 1525 | 0.000 |
Why?
|
Meningioma | 1 | 1976 | 1209 | 0.000 |
Why?
|
Child Behavior Disorders | 1 | 1993 | 807 | 0.000 |
Why?
|
Peripheral Nerves | 1 | 1971 | 466 | 0.000 |
Why?
|
Solvents | 1 | 1988 | 302 | 0.000 |
Why?
|
Rats, Inbred F344 | 1 | 1988 | 862 | 0.000 |
Why?
|
Perfusion | 1 | 1972 | 1360 | 0.000 |
Why?
|
Thiopental | 1 | 1967 | 59 | 0.000 |
Why?
|
Bone Marrow | 1 | 1977 | 2948 | 0.000 |
Why?
|
Heart Arrest | 1 | 1997 | 1470 | 0.000 |
Why?
|
Thalamus | 1 | 1973 | 1023 | 0.000 |
Why?
|
Cell Differentiation | 2 | 1981 | 11483 | 0.000 |
Why?
|
Thrombocytopenia | 1 | 1995 | 1179 | 0.000 |
Why?
|
Aggression | 1 | 1972 | 753 | 0.000 |
Why?
|
Skin Diseases | 1 | 1975 | 1065 | 0.000 |
Why?
|
Radioisotope Dilution Technique | 1 | 1966 | 70 | 0.000 |
Why?
|
Cycloparaffins | 1 | 1966 | 12 | 0.000 |
Why?
|
Consciousness | 1 | 1972 | 572 | 0.000 |
Why?
|
Histamine Release | 1 | 1966 | 142 | 0.000 |
Why?
|
Cell Line | 2 | 1997 | 15997 | 0.000 |
Why?
|
Pentobarbital | 1 | 1966 | 155 | 0.000 |
Why?
|
Methods | 2 | 1979 | 1129 | 0.000 |
Why?
|
Isocarboxazid | 1 | 1965 | 7 | 0.000 |
Why?
|
Polymers | 1 | 1973 | 1621 | 0.000 |
Why?
|
Terminology as Topic | 1 | 1993 | 1547 | 0.000 |
Why?
|
Hyperphagia | 1 | 1986 | 136 | 0.000 |
Why?
|
Droperidol | 1 | 1985 | 21 | 0.000 |
Why?
|
Anemia | 1 | 1995 | 1506 | 0.000 |
Why?
|
Ketones | 1 | 1966 | 188 | 0.000 |
Why?
|
Random Allocation | 1 | 1989 | 2429 | 0.000 |
Why?
|
Toxicology | 1 | 1965 | 106 | 0.000 |
Why?
|
Energy Metabolism | 1 | 1976 | 2899 | 0.000 |
Why?
|
Species Specificity | 1 | 1988 | 2478 | 0.000 |
Why?
|
Stress, Physiological | 1 | 1972 | 1403 | 0.000 |
Why?
|
Sexual Maturation | 1 | 1986 | 265 | 0.000 |
Why?
|
Niacinamide | 1 | 1966 | 417 | 0.000 |
Why?
|
Adrenocorticotropic Hormone | 1 | 1985 | 648 | 0.000 |
Why?
|
Exploratory Behavior | 1 | 1984 | 270 | 0.000 |
Why?
|
Intracranial Embolism and Thrombosis | 1 | 1982 | 148 | 0.000 |
Why?
|
Circular Dichroism | 1 | 1983 | 354 | 0.000 |
Why?
|
Learning | 1 | 1972 | 1713 | 0.000 |
Why?
|
Models, Biological | 1 | 1979 | 9583 | 0.000 |
Why?
|
Glioma | 1 | 1976 | 3401 | 0.000 |
Why?
|
Dogs | 1 | 1966 | 3912 | 0.000 |
Why?
|
Tomography, X-Ray Computed | 1 | 1985 | 20129 | 0.000 |
Why?
|
Cross Reactions | 1 | 1983 | 841 | 0.000 |
Why?
|
Radiometry | 1 | 1966 | 800 | 0.000 |
Why?
|
Heart Atria | 1 | 1967 | 1357 | 0.000 |
Why?
|
Posture | 1 | 1985 | 958 | 0.000 |
Why?
|
Peptides | 1 | 1973 | 4409 | 0.000 |
Why?
|
Culture Techniques | 1 | 1981 | 554 | 0.000 |
Why?
|
Aluminum Oxide | 1 | 1979 | 42 | 0.000 |
Why?
|
Feeding Behavior | 1 | 1972 | 3188 | 0.000 |
Why?
|
Adsorption | 1 | 1979 | 201 | 0.000 |
Why?
|
Glucose | 1 | 1970 | 4397 | 0.000 |
Why?
|
Microscopy, Electron | 1 | 1981 | 2645 | 0.000 |
Why?
|
Sleep | 1 | 1972 | 4623 | 0.000 |
Why?
|
Brain Neoplasms | 1 | 1976 | 8863 | 0.000 |
Why?
|
Nialamide | 1 | 1974 | 6 | 0.000 |
Why?
|
Astrocytoma | 1 | 1976 | 790 | 0.000 |
Why?
|
Cardiovascular Diseases | 1 | 1997 | 15165 | 0.000 |
Why?
|
Cerebral Hemorrhage | 1 | 1982 | 2647 | 0.000 |
Why?
|
Enzyme Activation | 1 | 1975 | 3701 | 0.000 |
Why?
|
Melatonin | 1 | 1972 | 721 | 0.000 |
Why?
|
Adenosine Triphosphate | 1 | 1972 | 2025 | 0.000 |
Why?
|
Uterus | 1 | 1966 | 711 | 0.000 |
Why?
|